Androgen News and Research RSS Feed - Androgen News and Research

New species of tRNA-derived small RNAs contribute to cell proliferation in cancer

New species of tRNA-derived small RNAs contribute to cell proliferation in cancer

Since their discovery in the 1950s, transfer RNAs (tRNAs) have been best known for their role in helping the cell make proteins from messenger RNA templates. However, recent studies have led to a previously-unsuspected concept that tRNAs are not always the end product; namely, they further serve as a source of small RNAs. [More]
Study reveals new information about role of abdominal fat in teens with CAH

Study reveals new information about role of abdominal fat in teens with CAH

Researchers at Children's Hospital Los Angeles have demonstrated that adolescents and young adults with congenital adrenal hyperplasia (CAH) have significantly increased amounts of abdominal fat tissue, placing them at greater risk for harmful conditions linked to obesity, including cardiovascular disease (CVD). [More]
Advanced prostate cancer patients who have AR-V7 gene variant respond to chemotherapy

Advanced prostate cancer patients who have AR-V7 gene variant respond to chemotherapy

In a small clinical trial, scientists at Johns Hopkins' Kimmel Cancer Center and James Buchanan Brady Urological Institute found that men with advanced prostate cancer and detection of androgen receptor splice variant-7 (AR-V7) respond to chemotherapy just as well as men who lack the variant. [More]
Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Astellas Pharma Inc. announced that data from a Phase 2 study evaluating the investigational use of enzalutamide as a single agent for the treatment of advanced androgen receptor (AR) positive, triple-negative breast cancer (TNBC) were presented during an oral abstracts session at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. [More]
Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from three studies that demonstrate the utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in facilitating comparisons between tumors that share histological features. [More]
Researchers identify key driver mutations in glioma samples that confirm tumor heterogeneity

Researchers identify key driver mutations in glioma samples that confirm tumor heterogeneity

Caris Life Sciences today announced the presentation of data from a study in which researchers identified biomarker changes, including key driver mutations, in 89% of metachronous paired glioma tumors, indicating changes in response to therapy as the disease progresses. [More]
ESSA Pharma reports net loss of $5.9 million for second quarter 2015

ESSA Pharma reports net loss of $5.9 million for second quarter 2015

ESSA Pharma Inc. today reported financial results for the second quarter and three and six months ended March 31, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with International Financial Reporting Standards. [More]
Clinical genomic sequencing could impact treatment decisions in advanced prostate cancer patients

Clinical genomic sequencing could impact treatment decisions in advanced prostate cancer patients

An international collaboration of researchers are advancing precision medicine to men with advanced prostate cancer. [More]
Severe OSA, excessive daytime sleepiness linked to increased risk of depression in men

Severe OSA, excessive daytime sleepiness linked to increased risk of depression in men

Severe obstructive sleep apnea (OSA) and excessive daytime sleepiness are associated with an increased risk of depression in men, according to a new community-based study of Australian men, which was presented at the 2015 American Thoracic Society International Conference. [More]
Prostate cancer patients can experience cognitive impairment following androgen deprivation therapy

Prostate cancer patients can experience cognitive impairment following androgen deprivation therapy

Cognitive impairment can occur in cancer patients who are treated with a variety of therapies, including radiation therapy, hormone therapy, and chemotherapy. [More]
Prostate cancer patients who receive androgen deprivation therapy may experience cognitive problems

Prostate cancer patients who receive androgen deprivation therapy may experience cognitive problems

Cognitive impairment can occur in cancer patients who are treated with a variety of therapies, including radiation therapy, hormone therapy, and chemotherapy. After chemotherapy treatment it is commonly called "chemo brain." Signs of cognitive impairment include forgetfulness, inability to concentrate, problems recalling information, trouble multi-tasking and becoming slower at processing information. [More]
Obese people at greater risk of developing cancer

Obese people at greater risk of developing cancer

Cancer is more likely to develop in people who are very overweight (obese), because surplus body fat interferes with various hormone cycles and with glucose and fat metabolism. On the occasion of European Obesity Day this coming Saturday (16 May), metabolic expert Alexandra Kautzky-Willer, Comprehensive Cancer Center at MedUni Vienna and Vienna General Hospital, draws attention to the fact that, even in Austria, more and more people are suffering from obesity. [More]
Moffitt scientists examine why prostate cancer patients who receive ADT experience hot flashes

Moffitt scientists examine why prostate cancer patients who receive ADT experience hot flashes

Androgen deprivation therapy (ADT) is a common treatment option for patients with advanced stage prostate cancer. But nearly 80 percent of patients who receive ADT report experiencing hot flashes during and after treatment. Moffitt Cancer Center researchers are working to determine what genetic factors and other characteristics might make prostate cancer patients more likely to experience hot flashes during and after therapy. [More]
Cholesterol-lowering statin drugs could delay prostate cancer growth in patients receiving ADT

Cholesterol-lowering statin drugs could delay prostate cancer growth in patients receiving ADT

Men who went on cholesterol-lowering statin drugs when they began androgen deprivation therapy for prostate cancer had a longer time in which their disease was under control than did men who didn't take statins, a clinical trial led by Dana-Farber Cancer Institute investigators shows. [More]
Noninvasive nuclear medicine test can help determine effectiveness of aromatase inhibitor treatment

Noninvasive nuclear medicine test can help determine effectiveness of aromatase inhibitor treatment

A new, noninvasive nuclear medicine test can be used to determine whether aromatase inhibitor treatment will be effective for specific cancer patients, according to a recent study reported in The Journal of Nuclear Medicine. [More]
Scientists solve mystery about the origin of ovarian cell

Scientists solve mystery about the origin of ovarian cell

Scientists at the National Institutes of Health have solved a long-standing mystery about the origin of one of the cell types that make up the ovary. The team also discovered how ovarian cells share information during development of an ovarian follicle, which holds the maturing egg. [More]
Transition Therapeutics acquires worldwide rights from Lilly to develop, commercialize TT701

Transition Therapeutics acquires worldwide rights from Lilly to develop, commercialize TT701

Transition Therapeutics Inc. today announced its wholly-owned subsidiary, Transition Therapeutics Ireland Limited, has exclusively licensed worldwide rights to a novel small molecule drug candidate ("TT701") from Eli Lilly and Company. [More]
Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2015. For the first quarter of 2015, the Company reported a net loss of $1.2 million, or $0.01 loss per share, compared to a net loss of $11.8 million, or $0.17 loss per share, for the same period in 2014. [More]
Men who receive brachytherapy more likely to be cancer-free five years later

Men who receive brachytherapy more likely to be cancer-free five years later

Results from a randomised controlled trial to compare the use of permanent radioactive implants (brachytherapy) with dose-escalated external beam radiotherapy in patients with prostate cancer show that the men who received brachytherapy were twice as likely to be cancer-free five years later. [More]
Study points to TMPRSS2 gene as culprit for aggressive forms of androgen-fuelled cancers

Study points to TMPRSS2 gene as culprit for aggressive forms of androgen-fuelled cancers

A new study led by University of Toronto researcher Dr. David Lam has discovered the trigger behind the most severe forms of cancer pain. Released in top journal Pain this month, the study points to TMPRSS2 as the culprit: a gene that is also responsible for some of the most aggressive forms of androgen-fuelled cancers. [More]
Advertisement
Advertisement